210 results on '"Morrow, Michelle"'
Search Results
2. De novo KCNA6 variants with attenuated KV1.6 channel deactivation in patients with epilepsy
3. Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report
4. A recurrent missense variant in the E3 ubiquitin ligase substrate recognition subunit FEM1B causes a rare syndromic neurodevelopmental disorder
5. Elucidating the clinical and molecular spectrum of SMARCC2-associated NDD in a cohort of 65 affected individuals
6. Novel NUDT2 variant causes intellectual disability and polyneuropathy.
7. De novo variants implicate chromatin modification, transcriptional regulation, and retinoic acid signaling in syndromic craniosynostosis
8. De novo missense variants in the E3 ubiquitin ligase adaptor KLHL20 cause a developmental disorder with intellectual disability, epilepsy, and autism spectrum disorder
9. Genomic and phenotypic characterization of 404 individuals with neurodevelopmental disorders caused by CTNNB1 variants
10. Leveraging cancer mutation data to inform the pathogenicity classification of germline missense variants.
11. Semaphorin-Plexin Signaling: From Axonal Guidance to a New X-Linked Intellectual Disability Syndrome
12. MYT1L-associated neurodevelopmental disorder: description of 40 new cases and literature review of clinical and molecular aspects
13. CDK19-related disorder results from both loss-of-function and gain-of-function de novo missense variants
14. Genetic Counseling at the Intersection of Clinical Genetics and Informatics
15. FIBCD1 is an endocytic GAG receptor associated with a novel neurodevelopmental disorder
16. Enhanced MAPK1 Function Causes a Neurodevelopmental Disorder within the RASopathy Clinical Spectrum
17. De novo missense variants in exon 9 of SEPHS1 cause a neurodevelopmental condition with developmental delay, poor growth, hypotonia, and dysmorphic features
18. MGA-related syndrome: A proposed novel disorder
19. Inferring disease course from differential exon usage in the wide titinopathy spectrum
20. A comparative medical genomics approach may facilitate the interpretation of rare missense variation
21. Leveraging cancer mutation data to predict the pathogenicity of germline missense variants
22. A comparative medical genomics approach may facilitate the interpretation of rare missense variation
23. Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments
24. Genetic Counseling at the Intersection of Clinical Genetics and Informatics
25. P829: Comparative medical genetics to facilitate the interpretation of rare missense variation
26. P014: Multiple cases of mosaic X-linked adrenoleukodystrophy in males identified through newborn screening
27. Weekly Proactive Telephone Breastfeeding Standard Care by Lactation Consultants in the First Month Postpartum Prolongs Breastfeeding for Up to 6 Months
28. Supplementary Figures from CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement
29. Data from CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement
30. Data from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
31. MEDI5752FINALSupplementaryMaterial.docx from Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells
32. Data from Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells
33. Supplementary Dataset from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
34. Supplementary Figures 1 through 5, Supplementary Tables 1 through 4, and Supplementary Methods from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
35. Elucidating the clinical and molecular spectrum ofSMARCC2-associated NDD in a cohort of 65 affected individuals
36. Supplementary Figures S1-S5 from A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
37. Supplemental Figure 4 from Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
38. Supplemental Figure 1 from Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
39. Supplemental Figure Legends from Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
40. Supporting information from A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
41. Supplemental Figure 6 from Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
42. Supplemental Figure 5 from Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
43. Supporting information tracked changes from A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
44. Supplementary figures from A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
45. Supplemental Figure 3 from Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
46. Kraman et al Supplementary Data from FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
47. Supplemental Figure 2 from Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
48. Data from Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
49. Data from ERG Is a Megakaryocytic Oncogene
50. Supplementary Methods from ERG Is a Megakaryocytic Oncogene
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.